Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 441 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Locally Advanced Solid Tumors Clear all
Active, not recruiting Phase 2 Interventional

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

NCT04940299
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Renal Pelvis Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Bladder Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Carcinoma, Metastatic Urethral Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v6, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Ipilimumab, Nivolumab, Tocilizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 23, 2026, 7:53 PM EDT
Recruiting Phase 1 Interventional

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

NCT06415487
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab
Drug
Lead sponsor
Acepodia Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
San Diego, California • Denver, Colorado • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jul 23, 2026, 7:53 PM EDT
Terminated Phase 1 Interventional

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06630247
View directory record Official record
Conditions
Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis
Interventions
XL495, ADC cytotoxic agents
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jul 23, 2026, 7:53 PM EDT
Recruiting Phase 1 Interventional

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

NCT06160752
View directory record Official record
Conditions
Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Interventions
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Jul 23, 2026, 7:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning

NCT04515810
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Hematologic Malignancy, Refractory Hematologic Malignancy
Interventions
Internet-Based Intervention, Best Practice, Telephone-Based Intervention, Questionnaire Administration, Post-intervention qualitative feedback interview
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Manhasset, New York • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 7:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

NCT04800627
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Pembrolizumab, Pevonedistat
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Jul 23, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT03602079
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
Interventions
A166
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Jul 23, 2026, 7:53 PM EDT
Terminated Phase 1 Interventional Results available

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

NCT04762602
View directory record Official record
Conditions
Isocitrate Dehydrogenase Gene Mutation
Interventions
HMPL-306
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 23, 2026, 7:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

NCT05862324
View directory record Official record
Conditions
Metastatic Solid Tumor
Interventions
TAC01-CLDN18.2
Biological
Lead sponsor
Triumvira Immunologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jul 23, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

ARQ 501 in Combination With Docetaxel in Patients With Cancer

NCT00099190
View directory record Official record
Conditions
Carcinoma
Interventions
ARQ 501
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2009 · Synced Jul 23, 2026, 7:53 PM EDT
Active, not recruiting Phase 1 Interventional

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

NCT02453620
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

NCT01986166
View directory record Official record
Conditions
Neoplasms
Interventions
Cobimetinib, MEHD7945A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Jul 23, 2026, 7:53 PM EDT
Recruiting Phase 2 Interventional

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

NCT07432295
View directory record Official record
Conditions
Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Interventions
Givastomig, Nivolumab, 5Fluorouracil, Leucovorin, Oxaliplatin, Capecitabine
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Goodyear, Arizona • Duarte, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 7:53 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116
View directory record Official record
Conditions
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
Oral repotrectinib (TPX-0005)
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
49
States / cities
Duarte, California • Glendale, California • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 7:53 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT04032704
View directory record Official record
Conditions
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
Interventions
ladiratuzumab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
27
States / cities
Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 23, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

NCT05867121
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
RO7496353, Atezolizumab, Capecitabine, S-1, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

NCT01325558
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
Interventions
ALT-836 in combination with gemcitabine
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Jul 23, 2026, 7:53 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

NCT03485209
View directory record Official record
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Interventions
tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
124
States / cities
Encinitas, California • La Jolla, California • Sacramento, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 7:53 PM EDT
Active, not recruiting Phase 1 Interventional

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02321501
View directory record Official record
Conditions
ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

NCT01327612
View directory record Official record
Conditions
Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors
Interventions
Modified FOLFOX6, Conatumumab, Ganitumab, Bevacizumab
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
10
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 23, 2026, 7:53 PM EDT
Recruiting Phase 1 Interventional

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559
View directory record Official record
Conditions
Solid Tumor
Interventions
Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil, Irinotecan, Nanoparticle albumin-bound-paclitaxel, Gemcitabine, Docetaxel, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Liposomal Irinotecan
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
25
States / cities
Duarte, California • Santa Monica, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 7:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

NCT04424641
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
Interventions
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jul 23, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

NCT03589651
View directory record Official record
Conditions
Unresectable or Metastatic Solid Tumors
Interventions
Retifanlimab, Epacadostat, INCB050465
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 23, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

NCT00526045
View directory record Official record
Conditions
Breast Cancer, Hematologic Neoplasms
Interventions
AUY922 2 mg/m2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
7
States / cities
Los Angeles, California • Augusta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 23, 2026, 7:53 PM EDT